Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. (2017)

First Author: Van Den Bent MJ
Attributed to:  CANCER: Trials with potential global reach and other challenging trials funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s0140-6736(17)31442-3

PubMed Identifier: 28801186

Publication URI: http://europepmc.org/abstract/MED/28801186

Type: Journal Article/Review

Volume: 390

Parent Publication: Lancet (London, England)

Issue: 10103

ISSN: 0140-6736